MedTrace Logo

Carbergoline for Antipsychotic Induced Hyperprolactinemia.

NCT07386080 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2026-02-04

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if cabergoline is safe to use in patients with antipsychotic-induced hyperprolactinemia in adults with scizophrenia. The main question it aims to answer :

Is the severity of positive and negative symptoms affected by the use of cabergoline?

Researchers will compare cabergolin to placebo to see if positive and negative symptoms are equel in both groups.

Participants will, in a blinded manor, take either placebo tablets or cabergoline for 12 weeks. The severity of positive and negative symptoms will be evaluated before and after the intervention in both groups.

Conditions

  • Scizophrenia

Interventions

DRUG

Cabergoline (Dopamine Agonist)

This intervention will use cabergoline for antipsychotic induced hyperprolactinemia.

DRUG

Placebo

Placebo + standard care

Sponsors & Collaborators

  • Region Zealand

    collaborator OTHER

  • Zealand University Hospital

    lead OTHER

Principal Investigators

  • Jesper Krogh · Zealand University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2028-05-01
Completion
2029-05-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07386080 on ClinicalTrials.gov